Covaxin triggers immune response, no adverse effects in phase 1 trial

India's first indigenous Covid-19 vaccine Covaxin, developed by Bharat Biotech in association with Indian Council of Medical research, was found to be "well tolerated in all dose groups with no vaccine-related serious adverse events," stated the interim findings of phase 1 trial of Covaxin.